There is increasing evidence that anti–PD-1/PD-L1 therapy is effective against malignant neoplasms, such as lung cancer (12, 13), melanoma (13, 14), Hodgkin’s lymphoma (15, 16), and renal cell carcinoma (13, 17). The gene discussed is PDCD1; the disease is cancer.